Related Experiment Video
Updated: May 15, 2026
Translational Orthotopic Models of Glioblastoma Multiforme
Published on: February 17, 2023
Immunohistochemical expression of PTTG in brain tumors
Fateme Salehi1, Bernd W Scheithauer, Soniya Sharma
1Department of Laboratory Medicine and Pathology, St. Michael's Hospital, 30 Bond Street, Toronto, ON, Canada. sfateme@gmail.com
Background:
Pituitary tumor-transforming gene (PTTG1) has been implicated in several oncogenic processes. The aim of this study was to determine PTTG expression in brain tumors.
Materials And Methods:
We investigated 88 benign and malignant brain tumors. PTTG immunoexpression was evaluated using a scale of 0 to 3. PTTG immunoexpression was nuclear and cytoplasmic in most tumors, except for medulloblastomas and hemangiopericytomas. Expression was highest in medulloblastomas. Higher grade gliomas including glioblastoma multiforme (GBM) IV and astrocytoma III had the highest level of PTTG expression, whereas low-grade gliomas had the lowest levels of PTTG expression. Hemangiopericytomas had the lowest levels of PTTG immunoreactivity, with meningiomas and schwannomas exhibiting similarly low PTTG levels. Nuclear PTTG immunoreactivity was higher than cytoplasmic in higher-grade tumors.
Conclusion:
Our results indicate that PTTG immunoexpression is higher in aggressive brain tumors including medulloblastomas, GBM IV, and astrocytoma III, whereas in more benign tumors, PTTG immunoexpression is lower.
